Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients

Cancer

Volumn 118, Issue 10, 2012, Pages 2603-2614

  Jung, Eun Jung ^a,b   Santarpia, Libero ^c   Kim, Juyeon ^b   Esteva, Francisco J ^a   Moretti, Erica ^c   Buzdar, Aman U ^a   Di Leo, Angelo ^c   Le, Xiao Feng ^a   Bast, Robert C ^a   Park, Soon Tae ^b   Pusztai, Lajos ^a   Calin, George A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Gyeongsang National University School of Medicine   (South Korea)

^c Hospital of Prato   (Italy)

Author keywords

breast cancer; microRNA; plasma; trastuzumab resistance

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; MICRORNA 126; MICRORNA 21; MICRORNA 210; MICRORNA 29A; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER RESISTANCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; LYMPH NODE METASTASIS; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; ONCOLOGICAL PARAMETERS; PATIENT MONITORING; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR PRESENCE; TUMOR VOLUME; UPREGULATION;

EID: 84860659806     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26565     Document Type: Article

References (38)

1. Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002; 20: 1467-1472.
2. Abramson V, Artega CL,. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin Cancer Res. 2011; 17: 952-958.
3. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17: 2639-2648.
4. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001; 19: 2587-2595.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
6. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23: 3676-3685.
7. Hardee ME, Eapen RJ, Rabbani ZN, et al. Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors. Cancer Chemother Pharmacol. 2009; 63: 219-228.
8. DeClerck K, Elble RC,. The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Front Biosci. 2010; 15: 213-225.
9. Niibe Y, Watanabe J, Tsunoda S, et al. Concomitant expression of HER2 and HIF-1alpha is a predictor of poor prognosis in uterine cervical carcinoma treated with concurrent chemoradiotherapy: prospective analysis (KGROG0501). Eur J Gynaecol Oncol. 2010; 31: 491-496.
10. Foekens JA, Sieuwerts AM, Smid M, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA. 2008; 105: 13021-13026.
11. Miska EA,. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 2005; 15: 563-568.
12. Camps C, Buffa FM, Colella S, et al. Hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008; 14: 1340-1348.
13. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65: 7065-7070.
14. Mattie MD, Benz CC, Bowers J, et al. Optimized high throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies [serial online]. Mol Cancer. 2006; 5: 24.
15. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18: 997-1006.
16. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141: 672-675.
17. Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009; 112: 55-59.
18. Feng G, Li G, Gentil-Perret A, et al. Elevated serum-circulating RNA in patients with conventional renal cell cancer. Anticancer Res. 2008; 28: 321-326.
19. Le X-F, Arachchige-Don AS, Mao W, Horne MC, Bast RC Jr,. Roles of HER2, JNK, PI3K, and p70S6K pathways in regulation of cyclin G2 in human breast cancer cells. Mol Cancer Ther. 2007; 6: 2843-2857.
20. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ,. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251: 499-505.
21. Volinia S, Galasso M, Costinean S, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010; 20: 589-599.
22. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006; 103: 2257-2261.
23. Gong C, Yao Y, Wang Y, et al. Upregulation of MIR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem. 2011; 286: 13714-12722.
24. Ivan M, Harris AL, Martelli F, et al. Hypoxia response and microRNA: no longer separate worlds. J Cell Mol Med. 2008; 12: 1426-1431.
25. Blower PE, Chung JH, Verducci JS, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008; 7: 1-9.
26. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterol. 2006; 30: 2113-2129.
27. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H,. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2010; 126: 73-80.
28. Ho AS, Huang X, Cao H, et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Translational Oncol. 2011; 3: 109-113.
29. Gee HE, Camps C, Buffa FM, et al. Hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 2010; 116: 2148-2158.
30. Salloum FN, Yin O, Kukreja RC,. Role of miRs in cardiac preconditioning. J Cardiovasc Pharmacol. 2010; 56: 581-588.
31. Mathe EA, Nguyen GH, Bowman ED, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res. 2009; 15: 6192-6200.
32. Li J, Huang H, Sun L, et al. MiR-210 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res. 2009; 15: 3998-4008.
33. Tsuchiya S, Fujiwara T, Sato F, et al. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). Biol Chem. 2011; 286: 420-428.
34. Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C,. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008; 68: 1471-1477.
35. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M,. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001; 93: 1852-1857.
36. Clark AS, West K, Streicher S, Dennis PA,. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002; 1: 707-717.
37. Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005; 65: 473-482.
38. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA,. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011; 8: 467-477.